Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology.
Suchowersky O, Armstrong MJ, Miyasaki J.
Neurology. 2013 Mar 5;80(10):970. doi: 10.1212/WNL.0b013e3182885eb3. No abstract available.
Related citations
One-year safety and tolerability profile of pridopidine in patients with Huntington disease.
Squitieri F, Landwehrmeyer B, Reilmann R, Rosser A, de Yebenes JG, Prang A, Ivkovic J, Bright J, Rembratt A.
Neurology. 2013 Mar 19;80(12):1086-94. doi: 10.1212/WNL.0b013e3182886965. Epub 2013 Feb 27.
Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease.
Stüwe SH, Goetze O, Lukas C, Klotz P, Hoffmann R, Banasch M, Orth M, Schmidt WE, Gold R, Saft C.
Neurology. 2013 Feb 19;80(8):743-6. doi: 10.1212/WNL.0b013e318282514e. Epub 2013 Feb 6.
The challenge of juvenile Huntington disease: to test or not to test.
Koutsis G, Karadima G, Kladi A, Panas M.
Neurology. 2013 Mar 12;80(11):990-6. doi: 10.1212/WNL.0b013e31828727fa. Epub 2013 Feb 6.
Family history in juvenile Huntington disease: do the signs point to "yes" or "very doubtful"?
Lehman RK, Nance M.
Neurology. 2013 Mar 12;80(11):976-7. doi: 10.1212/WNL.0b013e31828728ce. Epub 2013 Feb 6.
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease.
Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RL, Roos RA, Howland D, Detloff PJ, Housman DE, Bates GP.
Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2366-70. doi: 10.1073/pnas.1221891110. Epub 2013 Jan 22.
Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease.
Wang JQ, Chen Q, Wang X, Wang QC, Wang Y, Cheng HP, Guo C, Sun Q, Chen Q, Tang TS.
J Biol Chem. 2013 Feb 1;288(5):3070-84. doi: 10.1074/jbc.M112.407726. Epub 2012 Dec 17.
Prevalence estimates of Huntington disease in Caucasian populations are gross underestimates.
Morrison PJ.
Mov Disord. 2012 Nov;27(13):1707-8; author reply 1708-9. doi: 10.1002/mds.25266. No abstract available.
Mutant huntingtin impairs immune cell migration in Huntington disease.
Kwan W, Träger U, Davalos D, Chou A, Bouchard J, Andre R, Miller A, Weiss A, Giorgini F, Cheah C, Möller T, Stella N, Akassoglou K, Tabrizi SJ, Muchowski PJ.
J Clin Invest. 2012 Dec 3;122(12):4737-47. doi: 10.1172/JCI64484. Epub 2012 Nov 19.
Accounts of suicidality in the Huntington disease community.
Halpin M.
Omega (Westport). 2012;65(4):317-34.
A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease.
Yu-Taeger L, Petrasch-Parwez E, Osmand AP, Redensek A, Metzger S, Clemens LE, Park L, Howland D, Calaminus C, Gu X, Pichler B, Yang XW, Riess O, Nguyen HP.
J Neurosci. 2012 Oct 31;32(44):15426-38. doi: 10.1523/JNEUROSCI.1148-12.2012.
A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.
HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network.
JAMA Neurol. 2013 Jan;70(1):25-33. doi: 10.1001/2013.jamaneurol.382.
Determinants of fitness to drive in Huntington disease.
Devos H, Nieuwboer A, Tant M, De Weerdt W, Vandenberghe W.
Neurology. 2012 Nov 6;79(19):1975-82. doi: 10.1212/WNL.0b013e3182735d11. Epub 2012 Oct 24.
The unique co-occurrence of spinocerebellar ataxia type 10 (SCA10) and Huntington disease.
Roxburgh RH, Smith CO, Lim JG, Bachman DF, Byrd E, Bird TD.
J Neurol Sci. 2013 Jan 15;324(1-2):176-8. doi: 10.1016/j.jns.2012.09.030. Epub 2012 Oct 17.
Assessment of cortical and striatal involvement in 523 Huntington disease brains.
Hadzi TC, Hendricks AE, Latourelle JC, Lunetta KL, Cupples LA, Gillis T, Mysore JS, Gusella JF, MacDonald ME, Myers RH, Vonsattel JP.
Neurology. 2012 Oct 16;79(16):1708-15. doi: 10.1212/WNL.0b013e31826e9a5d. Epub 2012 Oct 3.
Poor insight into memory impairment in patients with Huntington disease.
Sitek EJ, Sołtan W, Robowski P, Schinwelski M, Wieczorek D, Sławek J.
Neurol Neurochir Pol. 2012 Jul-Aug;46(4):318-25.
A fully humanized transgenic mouse model of Huntington disease.
Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, Zhang W, Villanueva EB, Kovalik V, Xie Y, Pouladi MA, Collins JA, Yang XW, Franciosi S, Hayden MR.
Hum Mol Genet. 2013 Jan 1;22(1):18-34. doi: 10.1093/hmg/dds397. Epub 2012 Sep 21.
Development of the Huntington disease work function scale.
Brossman B, Williams JK, Downing N, Mills JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.
J Occup Environ Med. 2012 Oct;54(10):1300-8. doi: 10.1097/JOM.0b013e31825f30ab.
Abnormal apocrine secretory cell mitochondria in a Huntington disease patient.
Sidiropoulos C, LeWitt P, Hashimoto K.
J Neurol Sci. 2012 Dec 15;323(1-2):261-3. doi: 10.1016/j.jns.2012.08.034. Epub 2012 Sep 15.
Therapeutic approaches to preventing cell death in Huntington disease.
Kaplan A, Stockwell BR.
Prog Neurobiol. 2012 Dec;99(3):262-80. doi: 10.1016/j.pneurobio.2012.08.004. Epub 2012 Aug 28. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on